Clinical Trials on Non-small Cell Carcinoma in Mexico

Total 567 results

Seagen Inc.

Terminated

Denintuzumab Mafodotin (SGN-CD19A) Combined With RCHOP or RCHP Versus RCHOP Alone in Diffuse Large B-Cell Lymphoma or Follicular Lymphoma

Diffuse, Large B-Cell, Lymphoma | Follicular Lymphoma, Grade 3b | Transformed Lymphoma / DLBCL

United States, Puerto Rico
ECOG-ACRIN Cancer Research Group
National Cancer Institute (NCI)

Active, not recruiting

Cisplatin, Carboplatin and Etoposide or Temozolomide and Capecitabine in Treating Patients With Neuroendocrine Carcinoma of the Gastrointestinal Tract or Pancreas That Is Metastatic or Cannot Be Removed by Surgery

Gastric Neuroendocrine Carcinoma | Intestinal Neuroendocrine Carcinoma | Pancreatic Neuroendocrine Carcinoma

United States
Hoffmann-La Roche
Genentech, Inc.

Terminated

A Study of Bevacizumab (Avastin) in Combination With Rituximab (MabThera) and CHOP (Cyclophosphamide, Hydroxydaunorubicin [Doxorubicin], Oncovin [Vincristine], Prednisone) Chemotherapy in Patients With Diffuse Large B-cell Lymphoma

B-cell Lymphoma

Italy, China, United States, New Zealand, Canada, Australia, Austria, France, Spain, United Kingdom, Brazil, Colombia, Russian Federation, Thailand, Germany, Panama, Peru, Korea, Republic of, Hong Kong, Sweden, Argentina, Ecuador, P... and more
Celgene

Recruiting

Study to Compare the Effectiveness and Safety of Golcadomide Plus R-CHOP vs Placebo Plus R-CHOP in Participants With Previously Untreated High-risk Large B-cell Lymphoma (GOLSEEK-1)

Large B-cell Lymphoma

Korea, Republic of, Canada, United States, Argentina, Australia, Austria, Brazil, Bulgaria, Chile, China, Colombia, Croatia, Czechia, Denmark, Finland, France, Germany, Greece, Hungary, India, Japan, Malaysia, Mexico, New Zealand, Norway, Polan... and more
Bayer

Completed

Treatment Protocol for the Use of Sorafenib in Patients With Advanced Renal Cell Carcinoma

Carcinoma, Renal Cell

United States, Canada
National Cancer Institute (NCI)

Active, not recruiting

Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study

Clear Cell Renal Cell Carcinoma | Stage III Renal Cell Cancer AJCC v8 | Stage IV Renal Cell Cancer AJCC v8 | Metastatic Malignant Neoplasm in the Bone | Metastatic Malignant Neoplasm in the Lymph Nodes | Metastatic Malignant Neoplasm in the Soft Tissues | Metastatic Malignant Neoplasm in the Viscera and other conditions

United States, Puerto Rico
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Combination Chemotherapy in Treating Younger Patients With Newly Diagnosed, Non-metastatic Desmoplastic Medulloblastoma

Medulloblastoma | Nevoid Basal Cell Carcinoma Syndrome | Desmoplastic/Nodular Medulloblastoma | Medulloblastoma With Extensive Nodularity

United States, Canada, Puerto Rico, Australia
Genmab
AbbVie

Recruiting

A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administered in the Outpatient Setting in Adult Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma and Classic Follicular Lymphoma

Diffuse Large B-Cell Lymphoma | Classic Follicular Lymphoma

United States, Puerto Rico
Bristol-Myers Squibb
Ono Pharmaceutical Co. Ltd; Exelixis

Active, not recruiting

A Study of Nivolumab Combined With Cabozantinib Compared to Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 9ER)

Renal Cell Carcinoma

United States, Japan, Brazil, Argentina, Australia, Chile, Czechia, Germany, Greece, Israel, Italy, Mexico, Poland, Romania, Russian Federation, Spain, Turkey, United Kingdom
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

S0031, ZD 1839 in Treating Patients With Advanced Cancer of the Urinary Tract

Bladder Cancer | Transitional Cell Cancer of the Renal Pelvis and Ureter | Urethral Cancer

United States
National Cancer Institute (NCI)

Completed

Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma

Lymphoma

United States, Australia, South Africa, Peru, Puerto Rico
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: Taselisib as Therapy in Treating Patients With Stage IV Squamous Cell Lung Cancer and Positive Biomarker Matches

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma

United States, Canada
National Cancer Institute (NCI)
Gynecologic Oncology Group; NCIC Clinical Trials Group

Terminated

Cisplatin and Radiation Therapy With or Without Tirapazamine in Treating Patients With Cervical Cancer

Cervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Cervical Adenosquamous Cell Carcinoma

United States, Canada
Novartis Pharmaceuticals

Completed

Phase III Study of RAD001 Adjuvant Therapy in Poor Risk Patients With Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 Versus Matching Placebo After Patients Have Achieved Complete Response With First-line Rituximab-chemotherapy (PILLAR2)

Diffuse Large B-cell Lymphoma

China, United States, Colombia, Turkey, Spain, Egypt, Canada, Italy, Singapore, Australia, Austria, Czechia, Greece, Israel, Russian Federation, Hong Kong, Thailand, Korea, Republic of, Lebanon, Japan, Poland, Slovakia, Switzerland, G... and more
AVEO Pharmaceuticals, Inc.
Bristol-Myers Squibb; Parexel

Active, not recruiting

Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma

Renal Cell Carcinoma

Canada, Italy, Spain, United States, United Kingdom, Australia, Germany, Poland, Belgium, Portugal, Czechia, Brazil, France, Argentina, Chile, Mexico
MEI Pharma, Inc.

Terminated

Zandelisib (ME-401) in Subjects With Follicular Lymphoma or Marginal Zone Lymphoma After Failure of Two or More Prior Therapies (TIDAL)

Marginal Zone Lymphoma | Non Hodgkin Lymphoma | Follicular Lymphoma (FL)

United States, Spain, Korea, Republic of, Belgium, Taiwan, Germany, France, Italy, Australia, Poland, New Zealand, United Kingdom, Austria, Switzerland
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

Study of Ibrutinib (a Bruton's Tyrosine Kinase Inhibitor), Versus Temsirolimus in Patients With Relapsed or Refractory Mantle Cell Lymphoma Who Have Received at Least One Prior Therapy

Mantle Cell Lymphoma

France, Poland, United Kingdom, Belgium, Germany, Taiwan, Spain, Colombia, Portugal, Ukraine, Canada, Netherlands, Sweden, Korea, Republic of, Chile, Brazil, Russian Federation, Hungary, Ireland, Mexico, Czechia
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Identifying, Understanding, and Overcoming Barriers to the Use of Clinical Practice Guidelines in Pediatric Oncology

Hematopoietic and Lymphoid Cell Neoplasm | Malignant Solid Neoplasm | Acute Lymphoblastic Leukemia | B-Cell Non-Hodgkin Lymphoma | Recurrent Childhood Acute Lymphoblastic Leukemia | Childhood Acute Myeloid Leukemia | Childhood Burkitt Lymphoma | Childhood Neoplasm

United States, Puerto Rico
Alliance for Clinical Trials in Oncology
National Cancer Institute (NCI)

Active, not recruiting

Trying to Find the Correct Length of Treatment With Immune Checkpoint Therapy (IMAGINE)

Metastatic Bladder Urothelial Carcinoma | Metastatic Renal Pelvis Urothelial Carcinoma | Metastatic Ureter Urothelial Carcinoma | Metastatic Urethral Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Locally Advanced Bladder Urothelial Carcinoma | Locally Advanced Renal Pelvis Urothelial... and other conditions

United States
Seagen Inc.
Genentech, Inc.

Terminated

A Randomized Phase IIb Placebo-Controlled Study of R-ICE Chemotherapy With and Without SGN-40 for Patients With DLBCL

Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin

United States, France, Spain, Belgium, Australia, Germany, Poland, Italy, Czech Republic, Hungary
SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

Durvalumab and Tremelimumab in Treating Patients With Recurrent Stage IV Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States
SWOG Cancer Research Network
National Cancer Institute (NCI)

Completed

Lung-MAP: Biomarker-Targeted Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States, Canada
National Cancer Institute (NCI)
NRG Oncology; Canadian Cancer Trials Group

Active, not recruiting

Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer

Endometrial Clear Cell Adenocarcinoma | Endometrial Dedifferentiated Carcinoma | Endometrial Endometrioid Adenocarcinoma | Endometrial Mixed Cell Adenocarcinoma | Endometrial Serous Adenocarcinoma | Endometrial Undifferentiated Carcinoma | Recurrent Endometrial Adenocarcinoma | Recurrent Endometrial... and other conditions

United States, Korea, Republic of, Canada, Puerto Rico, Japan
Janssen Research & Development, LLC
Pharmacyclics LLC.

Active, not recruiting

A Study of the Bruton's Tyrosine Kinase Inhibitor Ibrutinib Given in Combination With Bendamustine and Rituximab in Patients With Newly Diagnosed Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States, France, Poland, United Kingdom, China, Belgium, Germany, Taiwan, Spain, Argentina, Israel, Turkey, Ukraine, Japan, Canada, Greece, Korea, Republic of, Netherlands, Brazil, Russian Federation, Puerto Rico, Australia, I... and more
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

Lung-MAP: Nivolumab With or Without Ipilimumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States, Canada
Millennium Pharmaceuticals, Inc.

Completed

Alisertib (MLN8237) or Investigator's Choice in Patients With Relapsed/Refractory Peripheral T-Cell Lymphoma

Refractory Peripheral T-Cell Lymphoma | Relapsed Peripheral T-Cell Lymphoma

United States, France, Italy, Poland, United Kingdom, Belgium, Germany, Spain, Belarus, Israel, Portugal, Bulgaria, Turkey, Canada, New Zealand, Peru, Brazil, Russian Federation, Chile, Puerto Rico, Australia, Austria, Hungary, Nether... and more
Children's Oncology Group
National Cancer Institute (NCI)

Completed

Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma

Lymphoma

United States, Canada, Australia, Switzerland, Puerto Rico
National Cancer Institute (NCI)

Recruiting

Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder for Bladder Cancer Treatment, MODERN Study

Stage III Bladder Urothelial Carcinoma AJCC v6 and v7 | Stage IV Bladder Urothelial Carcinoma AJCC v7 | Stage II Bladder Urothelial Carcinoma AJCC v6 and v7 | Muscle Invasive Bladder Urothelial Carcinoma

United States
Celldex Therapeutics

Completed

Phase III Study of Rindopepimut/GM-CSF in Patients With Newly Diagnosed Glioblastoma (ACT IV)

Glioblastoma | Gliosarcoma | Small Cell Glioblastoma | Giant Cell Glioblastoma | Glioblastoma With Oligodendroglial Component

United States, Canada, Australia, Israel, Taiwan, United Kingdom, Belgium, France, Spain, Germany, Austria, Brazil, Colombia, Czechia, Greece, Hungary, India, Italy, Mexico, Netherlands, New Zealand, Peru, Switzerland, Thailand
Janssen Research & Development, LLC
Pharmacyclics LLC.

Completed

A Study of the Bruton's Tyrosine Kinase Inhibitor, PCI-32765 (Ibrutinib), in Combination With Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

Lymphoma

United States, Australia, France, Poland, United Kingdom, China, Belgium, Germany, Spain, Israel, Turkey, Ukraine, Japan, Taiwan, Canada, Denmark, Finland, Korea, Republic of, Netherlands, Brazil, Russian Federation, Argentina, Norway, Swed... and more
Genzyme, a Sanofi Company

Active, not recruiting

An Efficacy Study Comparing ZD6474 to Placebo in Medullary Thyroid Cancer

Thyroid Cancer

United States, Australia, Austria, Belgium, Brazil, Canada, Czechia, Denmark, France, Germany, Hungary, India, Italy, Korea, Republic of, Mexico, Netherlands, Poland, Portugal, Romania, Russian Federation, Serbia, Spain, Sweden, Switz...
ImmunityBio, Inc.

Recruiting

A Study of Intravesical BCG in Combination With ALT-803 in Patients With Non-Muscle Invasive Bladder Cancer

Non-muscle Invasive Bladder Cancer

United States
National Cancer Institute (NCI)

Recruiting

Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma

Primary Mediastinal Large B-Cell Lymphoma

United States, Canada, Australia, Puerto Rico
Hoffmann-La Roche
Fondazione Italiana Linfomi ONLUS

Terminated

A Study of Obinutuzumab in Combination With CHOP Chemotherapy Versus Rituximab With CHOP in Participants With CD20-Positive Diffuse Large B-Cell Lymphoma (GOYA)

Diffuse Large B-Cell Lymphoma

Italy, China, Korea, Republic of, Canada, Australia, United States, Austria, Brazil, Denmark, Panama, Peru, Spain, Colombia, United Kingdom, Switzerland, Thailand, Mexico, Taiwan, Hong Kong, Russian Federation, Hungary, Japan, Germany, South Africa and more
zr Pharma & GmbH
Foundation Medicine

Terminated

Rucaparib in Patients With Locally Advanced or Metastatic Urothelial Carcinoma (ATLAS)

Bladder Cancer | Urothelial Carcinoma | Metastatic Urothelial Carcinoma | Muscle Invasive Bladder Cancer | Ureter Carcinoma | Renal Pelvis Carcinoma | Urinary Bladder Carcinoma | Urethra Carcinoma

United States, Spain, France, Italy, Germany, United Kingdom
Acerta Pharma BV
AstraZeneca

Active, not recruiting

A Combination of Acalabrutinib With R-CHOP in Subjects With Previously Untreated Non-GCB DLBCL (ACE-LY-312) (ESCALADE)

Diffuse Large B-Cell Lymphoma

United States, France, Italy, Spain, Canada, Taiwan, Germany, Korea, Republic of, Brazil, Japan, Russian Federation, Poland, China, Israel, Belgium, Australia, Austria, Czechia, Portugal, Mexico, Turkey, India, Ukraine
SWOG Cancer Research Network
National Cancer Institute (NCI); Genentech, Inc.

Recruiting

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

Diffuse Large B-Cell Lymphoma | Recurrent Diffuse Large B-Cell Lymphoma | Refractory Diffuse Large B-Cell Lymphoma | Primary Mediastinal (Thymic) Large B-Cell Lymphoma | Grade 3b Follicular Lymphoma | Transformed Follic Lymph to Diff Large B-Cell Lymphoma | Transformed Marg Zone Lymph to Diff...

United States
ImmunityBio, Inc.

Active, not recruiting

QUILT-3.032: A Multicenter Clinical Trial of Intravesical Bacillus Calmette-Guerin (BCG) in Combination With ALT-803 (N-803) in Patients With BCG Unresponsive High Grade Non-Muscle Invasive Bladder Cancer

Bladder Cancer

United States
Acerta Pharma BV
AstraZeneca

Active, not recruiting

A Study of BR Alone Versus in Combination With Acalabrutinib in Subjects With Previously Untreated MCL

Lymphoma, Mantle Cell

United States, France, Italy, Taiwan, Mexico, Russian Federation, Vietnam, Belgium, Canada, Brazil, Hungary, Japan, Poland, China, Spain, Germany, Australia, Czechia, Korea, Republic of, Israel, Romania, Ukraine, Argentina, Peru, New Zealand and more
National Cancer Institute (NCI)
NRG Oncology

Active, not recruiting

Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer

Recurrent Fallopian Tube Carcinoma | Recurrent Ovarian Carcinoma | Recurrent Primary Peritoneal Carcinoma | Ovarian Seromucinous Carcinoma | Recurrent Platinum-Resistant Ovarian Carcinoma | Primary Peritoneal High Grade Serous Adenocarcinoma | Ovarian High Grade Serous Adenocarcinoma | Fallopian... and other conditions

United States, Puerto Rico
Genmab
AbbVie

Recruiting

A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab Combined With Intravenous and Oral Rituximab, Cyclophosphamide, Doxorubicin Hydrochloride, Vincristine, and Prednisone (R-CHOP) or R-CHOP in Adult Participants With Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL) (EPCORE DLBCL-2)

Diffuse Large B-Cell Lymphoma

Korea, Republic of, Spain, Japan, Israel, Australia, Poland, Netherlands, Sweden, Greece, Taiwan, Italy, Denmark, Switzerland, France, Bulgaria, Hungary, Austria, New Zealand, Czechia, Croatia, Belgium, Brazil, China, United States, Canada and more
Merck Sharp & Dohme LLC

Recruiting

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

Chronic Lymphocytic Leukemia | Small Lymphocytic Leukemia

Poland, Turkey, Denmark, Singapore, Hungary, Hong Kong, Taiwan, Chile, Malaysia, Brazil, Guatemala, China, South Africa, Colombia, United States, Ukraine, Australia, Mexico, Romania
Children's Oncology Group
National Cancer Institute (NCI)

Recruiting

Study of Kidney Tumors in Younger Patients

Renal Cell Carcinoma | Wilms Tumor | Clear Cell Sarcoma of the Kidney | Papillary Renal Cell Carcinoma | Kidney Medullary Carcinoma | Diffuse Hyperplastic Perilobar Nephroblastomatosis | Rhabdoid Tumor of the Kidney | Congenital Mesoblastic Nephroma | Renal Cell Carcinoma Associated With Xp11.2 Translocations... and other conditions

United States, Canada, Puerto Rico, Australia, New Zealand, Israel, Switzerland
Merck Sharp & Dohme LLC

Active, not recruiting

Safety and Efficacy Study of Pembrolizumab (MK-3475) as Monotherapy in the Adjuvant Treatment of Renal Cell Carcinoma Post Nephrectomy (MK-3475-564/KEYNOTE-564)

Renal Cell Carcinoma

United States, Argentina, Australia, Brazil, Canada, Chile, Colombia, Czechia, Finland, France, Germany, Ireland, Italy, Japan, Korea, Republic of, Netherlands, Poland, Russian Federation, Spain, Taiwan, United Kingdom
Pharmacyclics Switzerland GmbH
Janssen Biotech, Inc., including Johnson & Johnson

Enrolling by invitation

Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib.

Lymphoma, B-Cell | Lymphoma, Non-Hodgkin | Solid Tumor | Leukemia, B-cell | Graft Vs Host Disease

United States, Spain, Taiwan, United Kingdom, Australia, Italy, Russian Federation, Canada, New Zealand, Korea, Republic of, France, Turkey, Czechia, Hungary, Poland, Sweden
Children's Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

Blood Sample Markers of Reproductive Hormones in Assessing Ovarian Reserve in Younger Patients With Newly Diagnosed Lymphomas

Lymphoma | Diffuse Large B-Cell Lymphoma | Hodgkin Lymphoma | Burkitt Lymphoma | Anaplastic Large Cell Lymphoma

United States, Canada
National Cancer Institute (NCI)

Completed

Brentuximab Vedotin or Crizotinib and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II-IV Anaplastic Large Cell Lymphoma

Anaplastic Large Cell Lymphoma, ALK-Positive | Ann Arbor Stage II Noncutaneous Childhood Anaplastic Large Cell Lymphoma | Ann Arbor Stage III Noncutaneous Childhood Anaplastic Large Cell Lymphoma | Ann Arbor Stage IV Noncutaneous Childhood Anaplastic Large Cell Lymphoma

United States
Southwest Oncology Group
National Cancer Institute (NCI)

Completed

Lung-MAP: Palbociclib as Second-Line Therapy in Treating Cell Cycle Gene Alteration Positive Patients With Recurrent Stage IV Squamous Cell Lung Cancer

CCND1 Gene Amplification | CCND2 Gene Amplification | CCND3 Gene Amplification | CDK4 Gene Amplification | Recurrent Squamous Cell Lung Carcinoma | Stage IV Squamous Cell Lung Carcinoma AJCC v7

United States
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Completed

Radiation Therapy in Treating Patients With Newly Diagnosed Brain Metastases From Kidney Cancer, Melanoma, or Sarcoma

Sarcoma | Kidney Cancer | Ovarian Cancer | Metastatic Cancer | Melanoma (Skin)

United States, Australia, Peru, Puerto Rico
Pfizer

Active, not recruiting

A Study of Avelumab With Axitinib Versus Sunitinib In Advanced Renal Cell Cancer (JAVELIN Renal 101)

Renal Cell Cancer

United States, Hungary, Spain, United Kingdom, Belgium, Korea, Republic of, Canada, Israel, Denmark, Australia, Italy, Japan, France, Austria, New Zealand, Romania, Russian Federation, Netherlands, Germany, Mexico, Sweden

Clinical Trials on Non-small Cell Carcinoma in Mexico

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ethiopia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations